http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104193791-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62a022b438611a1149c2fef2b5b5c232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87343f0391f5074a8ffb73f681e41648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcb35225a578542c5592310a91d18f18
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-044
filingDate 2003-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebaca215b83a18f651441fcaedb28929
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2769e553e2946e4ab6f77b6af140af55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c65dfec3b1f9941527425cc3f69283cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eaef76769c28b6a15e69948abbc8eb3
publicationDate 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-104193791-A
titleOfInvention Modified 2' and 3'-nucleoside prodrugs for the treatment of flavivirus infection
abstract The present invention relates to modified 2' and 3'-nucleoside prodrugs for the treatment of flavivirus infections, describing 2' and/or 3'-nucleoside prodrugs of 1', 2', 3' or 4'-branched Prodrugs, and their pharmaceutically acceptable salts and derivatives. These prodrugs are used in the prophylaxis and treatment of Flaviviridae infections, including HCV infections, and other related conditions. Compounds and compositions of the prodrugs of the invention are described. Also provided are methods and uses comprising administering an effective amount of a prodrug of the invention, or a pharmaceutically acceptable salt or derivative thereof. These agents may optionally be administered in combination or alternately with other antiviral agents to prevent or treat flavivirus infection and other related conditions.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111995649-A
priorityDate 2002-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0190121-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0192282-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0160315-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466985632
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467995500
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467147377
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467459088

Total number of triples: 66.